|
2025 Journal Article Estimation of transition probabilities from a large cohort (> 6000) of Australians living with Multiple Sclerosis (MS) for changing disability severity classifications, MS phenotype, and disease-modifying therapy classificationsCampbell, Julie A., Henson, Glen J., Ngwa, Valery Fuh, Ahmad, Hasnat, Taylor, Bruce V., van der Mei, Ingrid, Ramanathan, Sudarshini, Hardy, Todd A., Shaw, Cameron, Garber, Justin, Macdonell, Richard, McCombe, Pamela, John, Nevin, Hodgkinson, Suzanne, Walt, Anneke van der, Lechner-Scott, Jeannette, Roos, Izanne, Kalincik, Tomas, Carroll, William M., Fabis-Pedrini, Marzena, Kermode, Allan G., Butzkueven, Helmut, Palmer, Andrew J. and MSBase Australian Researchers (2025). Estimation of transition probabilities from a large cohort (> 6000) of Australians living with Multiple Sclerosis (MS) for changing disability severity classifications, MS phenotype, and disease-modifying therapy classifications. PharmacoEconomics, 43 (2) 102247, 223-239. doi: 10.1007/s40273-024-01417-4 |
|
2025 Journal Article Investigating the frequency of neural autoantibodies in refractory focal epilepsyGillinder, Lisa, Craig, Donald, Powell, Tamara, Walsh, Stephen, Phamnguyen, John, Wilson, Ian, Chen, Xiaohua, Gillis, David and McCombe, Pamela (2025). Investigating the frequency of neural autoantibodies in refractory focal epilepsy. Seizure: European Journal of Epilepsy, 125, 73-78. doi: 10.1016/j.seizure.2025.01.007 |
|
2025 Journal Article Routine blood biochemical biomarkers in amyotrophic lateral sclerosis: Systematic review and cohort analysisNona, Robert J., Henderson, Robert D. and McCombe, Pamela A. (2025). Routine blood biochemical biomarkers in amyotrophic lateral sclerosis: Systematic review and cohort analysis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26 (3-4), 1-19. doi: 10.1080/21678421.2024.2435976 |
|
2025 Journal Article Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2024), 10.1007/s40273-024-01417-4)Campbell, Julie A., Henson, Glen J., Ngwa, Valery Fuh, Ahmad, Hasnat, Taylor, Bruce V., van der Mei, Ingrid, Ramanathan, Sudarshini, Hardy, Todd A., Shaw, Cameron, Garber, Justin, Macdonell, Richard, McCombe, Pamela, John, Nevin, Hodgkinson, Suzanne, van der Walt, Anneke, Lechner-Scott, Jeannette, Roos, Izanne, Kalincik, Tomas, Carroll, William M., Fabis-Pedrini, Marzena, Kermode, Allan G., Butzkueven, Helmut and Palmer, Andrew J. (2025). Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2024), 10.1007/s40273-024-01417-4). PharmacoEconomics, 43 (2), 241-241. doi: 10.1007/s40273-024-01461-0 |
|
2025 Journal Article Persistent progression independent of relapse activity in multiple sclerosisZhu, Chao, Zhou, Zhen, Kalincik, Tomas, Roos, Izanne, Buzzard, Katherine, Skibina, Olga, Alroughani, Raed, Kuhle, Jens, Girard, Marc, Grammond, Pierre, Lechner-Scott, Jeannette, Gerlach, Oliver, John, Nevin, McCombe, Pamela, Macdonell, Richard, Van Pesch, Vincent, Laureys, Guy, Prevost, Julie, Horakova, Dana, Kubala Havrdova, Eva, Castillo-Triviño, Tamara, Ramo-Tello, Cristina, Blanco, Yolanda, Meca-Lallana, Jose E, Lugaresi, Alessandra, Tomassini, Valentina, Cartechini, Elisabetta, Amato, Maria Pia, Spitaleri, Daniele ... Butzkueven, Helmut (2025). Persistent progression independent of relapse activity in multiple sclerosis. Brain Communications, 7 (5) fcaf306, 1-11. doi: 10.1093/braincomms/fcaf306 |
|
2025 Journal Article Amyotrophic lateral sclerosis established as a multistep process across phenotypesZiser, Laura, van Eijk, Ruben P. A., Kiernan, Matthew C., McRae, Allan, Henderson, Robert D., Schultz, David, Needham, Merrilee, Mathers, Susan, McCombe, Pam, Talman, Paul and Vucic, Steve (2025). Amyotrophic lateral sclerosis established as a multistep process across phenotypes. European Journal of Neurology, 32 (1) e16532, e16532. doi: 10.1111/ene.16532 |
|
2024 Journal Article Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG–positive NMOSDSiriratnam, Pakeeran, Huda, Saif, Van Der Walt, Anneke, Sanfilippo, Paul G., Sharmin, Sifat, Foong, Yi Chao, Yeh, Wei Z., Zhu, Chao, Khoury, Samia J., Csepany, Tunde, Willekens, Barbara, Etemadifar, Masoud, Ozakbas, Serkan, Nytrova, Petra, Altintas, Ayse, Al-Asmi, Abdullah, Ramo-Tello, Cristina M., Laureys, Guy, Patti, Francesco, Horakova, Dana, Foschi, Matteo, Boz, Cavit, McCombe, Pamela A., Turkoglu, Recai, Lechner-Scott, Jeannette, Roos, Izanne, Kalincik, Tomas, Jokubaitis, Vilija G., Butzkueven, Helmut ... for MSBase (2024). Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG–positive NMOSD. Neurology, 103 (12) e209940, 1-8. doi: 10.1212/wnl.0000000000209940 |
|
2024 Conference Publication The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSharmin, Sifat, Roos, Izanne, Simpson-Yap, Steve, Malpas, Charles, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Kermode, Allan, Butler, Ernest, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Taylor, Bruce, Slee, Mark, Macdonell, Richard, Garber, Justin, Shaw, Cameron, Shuey, Neil, Massey, Jennifer, Hardy, Todd, Parratt, John and Kalincik, Tomas (2024). The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Australia: Progress in MS Research Conference (MS), Perth, WA, Australia, 29 November - 1 December 2023. London, United Kingdom: Sage Publications. |
|
2024 Journal Article Effectiveness of disease-modifying treatment on spinal cord lesion formation in relapse-onset multiple sclerosis: an MSBase registry studyKreiter, Daniel, Kalincik, Tomas, Hupperts, Raymond, Patti, Francesco, Spitaleri, Daniele, Foschi, Matteo, Surcinelli, Andrea, Maimone, Davide, Yamout, Bassem, Khoury, Samia J., Lechner-Scott, Jeannette, Ozakbas, Serkan, Gerlach, Oliver, Turkoglu, R., Soysal, A., Boz, C., Al-Asmi, A., Alkhaboori, J., Amato, M. P., Onofrj, M., Lugaresi, A., Besora, S., Sanchez-Menoyo, J. L., Lapointe, E., Grand’Maison, F., Grammond, P., Butzkueven, H., Van der Walt, A., Taylor, B. V. ... Barnett, M. H. (2024). Effectiveness of disease-modifying treatment on spinal cord lesion formation in relapse-onset multiple sclerosis: an MSBase registry study. CNS Drugs, 38 (11), 921-930. doi: 10.1007/s40263-024-01115-x |
|
2024 Conference Publication DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosisMaltby, Vicki E., Xavier, Alexandre, Monif, Mastura, Min, Myintzu, Fabis-Pedrini, Marzena J., Buzzard, Katherine, Kalincik, Tomas, Kermode, Allan G., Taylor, Bruce, Hodgkinson, Suzanne, McCombe, Pamela, Osborne, Meaghan, Butzkueven, Helmut, Barnett, Michael, Lea, Rodney A. and Lechner-Scott, Jeannette (2024). DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosis. Multiple Sclerosis Australia: Progress in MS Research Conference (MS), Perth, WA, Australia, 29 November - 1 December 2023. London, United Kingdom: Sage Publications. |
|
2024 Journal Article Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapiesYeh, Wei Z., Van Der Walt, Anneke, Skibina, Olga G., Kalincik, Tomas, Alroughani, Raed, Kermode, Allan G., Fabis-Pedrini, Marzena J., Carroll, William M., Lechner-Scott, Jeannette, Boz, Cavit, Ozakbas, Serkan, Buzzard, Katherine, Habek, Mario, John, Nevin A., Prat, Alexandre, Girard, Marc, Duquette, Pierre, Baghbanian, Seyed Mohammad, Hodgkinson, Suzanne, Van Pesch, Vincent, Laureys, Guy, Willekens, Barbara, Prevost, Julie, Foschi, Matteo, De Gans, Koen, Horakova, Dana, Havrdova, Eva Kubala, Karabudak, Rana, Patti, Francesco ... for the MSBase Study Group (2024). Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies. Neurology Neuroimmunology and Neuroinflammation, 11 (6) e200328, 1-16. doi: 10.1212/nxi.0000000000200328 |
|
2024 Journal Article Assessing the effect of Riluzole on motor unit discharge propertiesShandiz, Ehsan, Fernandes, Gabriel Lima, Henkin, Joao Saldanha, McCombe, Pamela Ann, Trajano, Gabriel Siqueira and Henderson, Robert David (2024). Assessing the effect of Riluzole on motor unit discharge properties. Brain Sciences, 14 (11) 1053, 1053. doi: 10.3390/brainsci14111053 |
|
2024 Journal Article Diagnosing late-onset Tay-Sachs through next generation sequencing and functional enzyme testing: from genes to enzymesTupil, Ajay R., Rivlin, Warwick, Mccombe, Pamela A., Henderson, Robert D., Rodgers, Jonathan and Vadlamudi, Lata (2024). Diagnosing late-onset Tay-Sachs through next generation sequencing and functional enzyme testing: from genes to enzymes. Neurology Genetics, 10 (6) e200205, e200205. doi: 10.1212/nxg.0000000000200205 |
|
2024 Conference Publication Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaborationLaing, N., Kennerson, M., Lamont, P., Vucic, S., Davis, M., Bryson-Richardson, R., Ravenscroft, G., Perez-Siles, G., Ghaoui, R., Narayanan, R., McCombe, P., Deveson, I., Bryen, S., Grosz, B., Johari, M., Rick, A., Folland, C., Scriba, C., Parmar, J. and Ellis, M. (2024). Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaboration. 29th International Congress of the World-Muscle-Society (WMS), Prague, Czech Republic, 8-12 October 2024. London, United Kingdom: Elsevier. doi: 10.1016/j.nmd.2024.07.328 |
|
2024 Journal Article Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studySiriratnam, Pakeeran, Sanfilippo, Paul, van der Walt, Anneke, Sharmin, Sifat, Foong, Yi Chao, Yeh, Wei Zhen, Zhu, Chao, Khoury, Samia Joseph, Csepany, Tunde, Willekens, Barbara, Etemadifar, Masoud, Ozakbas,, Serkan, Nytrova, Petra, Altintas, Ayse, Al-Asmi, Abdullah, Yamout, Bassem, Laureys, Guy, Patti, Francesco, Simo, Magdolna, Surcinelli, Andrea, Foschi, Matteo, McCombe, Pamela A, Alroughani, Raed, Sánchez-Menoyo, José Luis, Turkoglu, Recai, Soysal, Aysun, Lechner Scott, Jeanette, Kalincik, Tomas, Butzkueven, Helmut ... Monif, Mastura (2024). Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 96 (4) jnnp-2024-334090, 1-9. doi: 10.1136/jnnp-2024-334090 |
|
2024 Conference Publication Real-world experience with Cladribine (Mavenclad) in the MSBase registryButzkueven, Helmut, Spelman, Tim, Van der Walt, Anneke, Hodgkinson, Suzanne, Ozakbas, Serkan, Alroughani, Raed, Kalincik, Tomas, Eichau, Sara, Boz, Cavit, Buzzard, Katherine, Habek, Mario, John, Nevin, Kermode, Allan G., Foschi, Matteo, McCombe, Pamela, Gerlach, Oliver, Prevost, Julie, Meca-Lallana, Jose E., Lapointe, Emmanuelle and Jarvinen, Elina (2024). Real-world experience with Cladribine (Mavenclad) in the MSBase registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications. |
|
2024 Conference Publication Real-world Australian experience with Ofatumumab in the MSBase RegistryBarnett, Michael, van der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Hodgkinson, Suzanne, McCombe, Pamela, Macdonell, Richard, Slee, Mark, Migocki, Margaret, Martel, Kate and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase Registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications. |
|
2024 Journal Article Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisRoos, Izanne, Sharmin, Sifat, Malpas, Charles, Ozakbas, Serkan, Lechner-Scott, Jeannette, Hodgkinson, Suzanne, Alroughani, Raed, Eichau Madueño, Sara, Boz, Cavit, van der Walt, Anneke, Butzkueven, Helmut, Buzzard, Katherine, Skibina, Olga, Foschi, Matteo, Grand’Maison, Francois, John, Nevin, Grammond, Pierre, Terzi, Murat, Prévost, Julie, Barnett, Michael, Laureys, Guy, Van Hijfte, Liesbeth, Luis Sanchez-Menoyo, Jose, Blanco, Yolanda, Oh, Jiwon, McCombe, Pamela, Ramo Tello, Cristina, Soysal, Aysun, Prat, Alexandre ... Kalincik, Tomas (2024). Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 30 (9), 1163-1175. doi: 10.1177/13524585241267211 |
|
2024 Conference Publication Utilisation of high efficacy therapy for managing multiple sclerosis in AustraliaMcCombe, Pamela, Butzkueven, Helmut, Samjoo, Imtiaz, Barnett, Michael, Broadley, Simon, Walt, Anneke Van der, Merschhemke, Martin, Adlard, Nicholas, Burke, Naomi, Riley, Nicholas and Walker, Rob (2024). Utilisation of high efficacy therapy for managing multiple sclerosis in Australia. ANZAN Annual Scientific Meeting 2024, Adelaide, SA Australia, 21-24 May 2024. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2024-anzan.23 |
|
2024 Conference Publication Real-world Australian experience with Ofatumumab in the MSBase registryMigocki, Margaret, Walt, Anneke Van der, Butzkueven, Helmut, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Kalincik, Tomas, Macdonell, Richard, Slee, Mark and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase registry. ANZAN Annual Scientific Meeting 2024, Adelaide, SA Australia, 21-24 May 2024. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2024-anzan.127 |
